Budget impact analysis of enzalutamide for treatment of metastatic castration-resistant prostate cancer from a u.s. Payer perspective
Abstract
Authors
C.N. Bui K. O’Day S. Flanders N. Oestreicher P. Francis L. Posta B. Popelar H. Tang M. Balk